This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Abriff, fluticasone propionate/formoterol fumarate, Iffeza (EU), Flofera (EU), Flutiformo (EU), KRP-108 (Japan)
Description: Flutiform is a fixed-dose combination of the inhaled corticosteroid fluticasone with the long-acting bronchodilator formoterol in an HFA-powered metered-dose aerosol inhaler.
Flutiform 250/10 ug delivers 125 ug of fluticasone propionate per actuation and 5 ug of formoterol fumarate per actuation. Flutiform 100/10 ug delivers 100 ug of fluticasone propionate per actuation and 5 ug of formoterol fumarate per actuation. Patients take 2 actuations BID.
Kos and SkyePharma
In May 2006, SkyePharma and Kos Pharmaceuticals agreed to jointly develop Flutiform. Kos will have exclusive rights to market Flutiform in the United States and a right of first negotiation in Canada. SkyePharma could receive up to $165 million in milestone payments on achievement of all regulatory and revenue targets (of which $25 million was paid upfront) together with royalties starting in mid-teens on sales by Kos.
Mundipharma and SkyePharma
In September 2006, SkyePharma entered into an agreement with Mundipharma for the development, marketing and distribution of Flutiform. Mundipharma will have exclusive rights to market Flutiform in Europe and other territories outside North, Central and South America, with an option to negotiate for exclusive rights in Japan. SkyePharma received an upfront payment of EUR 15 million ($19 million) on signature and will receive additional milestone payments of up to a further EUR 70 million ($90 million)...See full deal structure in Biomedtracker
Partners: Mundipharma International Limited Kyorin Pharmaceutical Co., Ltd. Sanofi
Additional information available to subscribers only: